| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019 | 1211 | 2019 |
| The complex link between NAFLD and type 2 diabetes mellitus—mechanisms and treatments G Targher, KE Corey, CD Byrne, M Roden Nature reviews Gastroenterology & hepatology 18 (9), 599-612, 2021 | 642 | 2021 |
| Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis ZM Younossi, R Loomba, QM Anstee, ME Rinella, E Bugianesi, ... Hepatology 68 (1), 349-360, 2018 | 477 | 2018 |
| AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review ZM Younossi, KE Corey, JK Lim Gastroenterology 160 (3), 912-918, 2021 | 411 | 2021 |
| Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis ZM Younossi, R Loomba, ME Rinella, E Bugianesi, G Marchesini, ... Hepatology 68 (1), 361-371, 2018 | 407 | 2018 |
| Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials SA Harrison, VWS Wong, T Okanoue, N Bzowej, R Vuppalanchi, ... Journal of hepatology 73 (1), 26-39, 2020 | 406 | 2020 |
| Hepatocyte TAZ/WWTR1 promotes inflammation and fibrosis in nonalcoholic steatohepatitis X Wang, ZE Zheng, JM Caviglia, KE Corey, TM Herfel, B Cai, R Masia, ... Cell metabolism 24 (6), 848-862, 2016 | 393 | 2016 |
| Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis A Mantovani, A Csermely, G Petracca, G Beatrice, KE Corey, TG Simon, ... The lancet Gastroenterology & hepatology 6 (11), 903-913, 2021 | 386 | 2021 |
| Secondary causes of nonalcoholic fatty liver disease JM Kneeman, J Misdraji, KE Corey Therapeutic advances in gastroenterology 5 (3), 199-207, 2012 | 343 | 2012 |
| Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis KE Corey, SM Schmitz, NJ Shaheen The American journal of gastroenterology 98 (11), 2390-2394, 2003 | 271 | 2003 |
| Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up KE Corey, E Kane, C Munroe, LL Barlow, H Zheng, RT Chung Hepatology 50 (4), 1030-1037, 2009 | 238 | 2009 |
| Shear-wave elastography for the estimation of liver fibrosis in chronic liver disease: determining accuracy and ideal site for measurement AE Samir, M Dhyani, A Vij, AK Bhan, EF Halpern, J Méndez-Navarro, ... Radiology 274 (3), 888-896, 2015 | 234 | 2015 |
| The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: a multi-center study FC Stanford, N Alfaris, G Gomez, ET Ricks, AP Shukla, KE Corey, JS Pratt, ... Surgery for Obesity and Related Diseases 13 (3), 491-500, 2017 | 219 | 2017 |
| Association between aspirin use and risk of hepatocellular carcinoma TG Simon, Y Ma, JF Ludvigsson, DQ Chong, EL Giovannucci, CS Fuchs, ... JAMA oncology 4 (12), 1683-1690, 2018 | 215 | 2018 |
| Macrophage MerTK promotes liver fibrosis in nonalcoholic steatohepatitis B Cai, P Dongiovanni, KE Corey, X Wang, IO Shmarakov, Z Zheng, ... Cell metabolism 31 (2), 406-421. e7, 2020 | 211 | 2020 |
| Obesity and liver disease: the epidemic of the twenty-first century KE Corey, LM Kaplan Clinics in liver disease 18 (1), 1-18, 2014 | 168 | 2014 |
| Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: results from two prospective cohort studies TG Simon, LY King, DQ Chong, LH Nguyen, Y Ma, T VoPham, ... Hepatology 67 (5), 1797-1806, 2018 | 161 | 2018 |
| Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease TG Simon, J Henson, S Osganian, R Masia, AT Chan, RT Chung, ... Clinical Gastroenterology and Hepatology 17 (13), 2776-2784. e4, 2019 | 154 | 2019 |
| Advanced fibrosis is associated with incident cardiovascular disease in patients with non‐alcoholic fatty liver disease JB Henson, TG Simon, A Kaplan, S Osganian, R Masia, KE Corey Alimentary pharmacology & therapeutics 51 (7), 728-736, 2020 | 148 | 2020 |
| NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment G Targher, KE Corey, CD Byrne Diabetes & metabolism 47 (2), 101215, 2021 | 146 | 2021 |
